Status:
COMPLETED
Cytokines and Genes in Therapeutic Response in Crohn's Disease
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Inflammatory bowel disease (IBD), consisting of two major forms, Crohn's disease (CD) and ulcerative colitis (UC), affects more than 1.6 million people in the United States alone. Though the precise m...
Eligibility Criteria
Inclusion
- Patients that are seen in the Inflammatory Bowel Disease clinic with Crohn's disease who are initiating either treatment as part of their routine clinical care.
- Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication.
Exclusion
- pregnant
- have a known coagulopathy or bleeding disorder
- have known renal or hepatic impairment
- have a history of organ transplantation
- CD patients who are being seen in consultation and do not plan to receive longitudinal care through initiation their new therapy at the Vanderbilt IBD center will be excluded.
Key Trial Info
Start Date :
October 13 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 3 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT03266471
Start Date
October 13 2017
End Date
May 3 2022
Last Update
April 14 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Inflammatory Bowel Disease Clinic, Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212
2
Vanderbilt University Medical Center Endoscopy Laboratory
Nashville, Tennessee, United States, 37232